Literature DB >> 12439153

Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA.

S Gallistl1, G Cvirn, B Leschnik, W Muntean.   

Abstract

Activated prothrombin complex concentrates (APCCs) are effective in the therapy of bleeding episodes in hemophilic patients with inhibitors. We investigated the respective roles of factor II, factor VII, factor IX, and factor X in the procoagulant activity of the APCC FEIBA. Factor II, factor VII, factor IX, and factor X were reduced in platelet-poor plasma, and the thrombin potential (TP) was determined using a chromogenic substrate in the absence or presence of FEIBA. Reduction of factor II resulted in a significant decrease of the TP without influencing the lag phase until the onset of thrombin generation. The reduction of factor VII showed no effect on the TP, but resulted in a prolongation of the lag phase. Changes of factor IX or factor X concentrations showed neither an effect on the TP nor on lag phases. Our study demonstrates that thrombin generation in the presence of FEIBA mainly depends on prothrombin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439153     DOI: 10.1097/00001721-200210000-00012

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

Review 1.  Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity.

Authors:  Benny Sørensen; Donat R Spahn; Petra Innerhofer; Michael Spannagl; Rolf Rossaint
Journal:  Crit Care       Date:  2011-01-12       Impact factor: 9.097

2.  Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy.

Authors:  Nadia I Awad; Craig Cocchio
Journal:  P T       Date:  2013-11

3.  Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.

Authors:  Joost J van Veen; Kingsley K Hampton; Rhona Maclean; Fiona Fairlie; Michael Makris
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.